Back to Search
Start Over
Hypersomnia Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Takeda, KemPharm, Orexia, Pfizer, Eisai, Axsome Therapeutics
- Source :
- M2 Presswire. October 17, 2023
- Publication Year :
- 2023
-
Abstract
- M2 PRESSWIRE-October 17, 2023-: Hypersomnia Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Takeda, KemPharm, Orexia, Pfizer, Eisai, Axsome Therapeutics (C)1994-2023 M2 [...]
- Subjects :
- Pfizer Inc. -- Product development -- Forecasts and trends
Business -- Research
Clinical trials -- Forecasts and trends -- Reports
Hypersomnia -- Forecasts and trends -- Reports
Pharmaceutical industry -- Product development -- Forecasts and trends
Market trend/market analysis
Business
Business, international
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- M2 Presswire
- Publication Type :
- News
- Accession number :
- edsgcl.769210461